PATENT CLAIM ANALYSIS

Application Number: 15950707
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "170000"]

Abstract:
Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

Claim (Index 25):
The method according to  claim 1 , comprising administering the niraparib and the abiraterone acetate to the patient once per day over multiple days, and increasing the dosage of one or both of the niraparib and abiraterone acetate at least once over time.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.75758
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13034340', '14607732', '15551708', '15852551', '15337274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.696776337736763
- 35 USC 102 Novelty (BERT): 0.528510739344335
- Combined Prediction Score: 0.6799497778975201
- Mean Citation Score: 276.71241000000003
- Max Citation Score: 306.766
- Similarity Product: 202.6885496990681

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test